Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR-04 for EGFR inhibitor-associated rash prevention
NCT04731259Phase 2Withdrawn
- Sponsor
- Azitra, Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Fecal Microbiota Transplantation (FMT), Live Biotherapeutic Products, Engineered Microbial Therapeutics
01
Overview
A Phase 2 trial of ATR04-484 in papulopustular rash, sponsored by Azitra, Inc.. Planned start Jan 2024; status: withdrawn.
02
Drugs
ATR04-484
03
Conditions
papulopustular rash
Beyond the preview
Go deeper on NCT04731259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731259.